We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 4

1.
Figure 1

Figure 1. From: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

MAP-tau expression and frequency distribution in Yale University cohort with two-fold redundancy. (a) Representative case from the Yale University cohort TMA showing cytoplasmic localization of MAP-tau within breast tumor tissue (two-fold redundancy; n = 651). (i) Pixel binary gating demarcating epithelial tumor area from stroma in order to define the tumor compartment; (ii) immunofluorescence of MAP-tau-Cy5 (red) expression pattern (continuous score of 789); (iii) target protein MAP-tau-Cy5 (red) colocalization with cytokeratin-Cy3, a marker for breast epithelia (green); (iv) Localization of nuclear DAPI (blue) relative to colocalization of target protein MAP-tau-Cy5 (red) with cytokeratin-Cy3, a marker for breast epithelia (green). Original magnification x20. (b) Yale frequency distribution of average MAP-tau expression scores in the Yale University cohort with preselected cutpoint 462, the median MAP-tau expression score observed in normal breast tissue and used to differentiate high expressors from low expressors.

Maria T Baquero, et al. Breast Cancer Res. 2011;13(5):R85-R85.
2.
Figure 2

Figure 2. From: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Kaplan Meier survival analysis and MAP-tau expression in Yale University cohort. (a) Ten-year survival for high MAP-tau expression versus low expression for all invasive breast carcinoma patients in the Yale University cohort (n = 651). Survival rate for patients classified as high MAP-tau expressors (n = 94) was 68.3% compared with 52.9% for low expressors (n = 339; log-rank, P = 0.006). (b) Kaplan Meier survival for MAP-tau expression stratified by eatrogen receptor (ER) status in the Yale University cohort. For ER-negative patients (inset), high MAP-tau expression (n = 35) showed improved survival compared with low (n = 209) expression. (c) Ten-year survival for MAP-tau expression stratified by human epidermal growth factor receptor (HER) 2 status in the Yale University cohort. Patients classified as high MAP-Tau expressors showed improved survival compared with low expressors, regardless of HER2 status. For ER-negative patients stratified by HER2 status (inset), ER-negative patients with high MAP-tau expression (n = 30) trended toward improved survival, regardless of HER2 status, compared with low MAP-tau expressors (n = 56) (68.4% v 45.3%; log-rank, P = 0.068).

Maria T Baquero, et al. Breast Cancer Res. 2011;13(5):R85-R85.
3.
Figure 4

Figure 4. From: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Progression free survival by treatment arm and MAP-tau status in TAX 307S whole tissue sections. (a) Survival analysis for TAC vs FAC-treated patients (not stratified by MAP-tau) in TAX 307S indicated no treatment difference for TTP and confirmed original TAX 307 clinical trial results (n = 484). (B) Median progression free survival for patients classified as high MAP-tau expressors (n = 35) was 33.0 v 23.4 months compared with low expressors (n = 73) with mean TTP of 31.2 months (log-rank, P = 0.010). (c) Median progression-free survival for MAP-tau expression stratified by TAC or FAC treatment showing strong prognostic value for MAP-tau. Progression-free survival of 35.5 and 31.7 months for high MAP-tau expression, regardless of treatment arm (TAC or FAC/Tau high, n = 20, n = 15, respectively) compared with 20.6 and 25.0 months for low MAP-tau expression (TAC or FAC/Tau low, n = 34, n = 39), respectively indicating strong prognostic value for MAP-tau (log-rank, P = 0.006). (d) Kaplan Meier survival analysis for MAP-tau expression stratified by estrogen receptor (ER) status showing no association between ER status and MAP-tau expression (P = 0.0615).

Maria T Baquero, et al. Breast Cancer Res. 2011;13(5):R85-R85.
4.
Figure 3

Figure 3. From: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

MAP-tau expression and frequency distribution in TAX 307S whole tissue sections. (a) Whole section breast tumor tissue from patient case 24 stained with hematoxylin and eosin showing dark pink staining of tumor cytoplasm compared with blue nuclei staining (red arrows); remaining light pink or non-staining, mesh-like areas comprised of breast adipose tissue (black arrow). Original magnification × 4. (b) Whole tissue slide of breast tumor tissue from panel a (case 24) stained with MAP-tau-Cy5 and analyzed using AQUA digital pathology algorithms. A matrix captured 103 quadrants (41 quadrants displayed in panel b and was used to systematically capture each field of view (FOV), creating 103 unique expression scores for case 24. Original magnification × 4. (c) Frequency distribution for MAP-tau quadrant scores from case 24 with mean and median AQUA scores of 1357 and 1369, respectively, and a score range of 610 to 1986. FOVs were used to generate a frequency distribution for each case in the TAX 307S cohort (n = 140). The median AQUA score from each case was used in all cohort analyses. (d) Distribution of MAP-tau expression in TAX307.

Maria T Baquero, et al. Breast Cancer Res. 2011;13(5):R85-R85.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk